D C Talbot

1.0k total citations
26 papers, 748 citations indexed

About

D C Talbot is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D C Talbot has authored 26 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D C Talbot's work include Lung Cancer Research Studies (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Treatments and Mutations (6 papers). D C Talbot is often cited by papers focused on Lung Cancer Research Studies (8 papers), Cancer therapeutics and mechanisms (6 papers) and Lung Cancer Treatments and Mutations (6 papers). D C Talbot collaborates with scholars based in United Kingdom, Netherlands and Finland. D C Talbot's co-authors include Adrian L. Harris, Kenneth J. O’Byrne, Alexandra Giatromanolaki, Stephen Fox, Kevin C. Gatter, R Whitehouse, W.P. Steward, Jeremy Braybrooke, Tony Hope and Mark Saunders and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and British Journal of Cancer.

In The Last Decade

D C Talbot

26 papers receiving 727 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D C Talbot United Kingdom 14 383 343 277 149 55 26 748
Els O. Witteveen Netherlands 14 536 1.4× 434 1.3× 178 0.6× 158 1.1× 42 0.8× 23 1.1k
Pentti J. Taskinen Finland 16 465 1.2× 343 1.0× 310 1.1× 235 1.6× 15 0.3× 35 1.3k
Ines Abbate Italy 17 301 0.8× 280 0.8× 214 0.8× 88 0.6× 31 0.6× 46 844
Darlene Gibbon United States 15 325 0.8× 375 1.1× 109 0.4× 115 0.8× 55 1.0× 38 834
Patrizia Serra Italy 19 593 1.5× 277 0.8× 244 0.9× 261 1.8× 18 0.3× 51 1.0k
Adam Maciejczyk Poland 17 380 1.0× 371 1.1× 176 0.6× 140 0.9× 32 0.6× 85 915
Yiqun Zhang United States 17 346 0.9× 288 0.8× 143 0.5× 138 0.9× 48 0.9× 36 805
Qing Zhou China 19 487 1.3× 350 1.0× 150 0.5× 203 1.4× 29 0.5× 62 1.1k
P. Dodion Belgium 20 446 1.2× 484 1.4× 106 0.4× 204 1.4× 64 1.2× 72 1.1k
CA Eekman Netherlands 8 465 1.2× 384 1.1× 96 0.3× 64 0.4× 156 2.8× 8 725

Countries citing papers authored by D C Talbot

Since Specialization
Citations

This map shows the geographic impact of D C Talbot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D C Talbot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D C Talbot more than expected).

Fields of papers citing papers by D C Talbot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D C Talbot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D C Talbot. The network helps show where D C Talbot may publish in the future.

Co-authorship network of co-authors of D C Talbot

This figure shows the co-authorship network connecting the top 25 collaborators of D C Talbot. A scholar is included among the top collaborators of D C Talbot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D C Talbot. D C Talbot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woodcock, Victoria K., et al.. (2016). 20 Transformation of EML4/ALK positive adenocarcinoma of the lung to small cell lung cancer following ALK targeted therapy. Lung Cancer. 91. S8–S8. 1 indexed citations
2.
Schaefer, Eric, Martin Förster, D C Talbot, et al.. (2016). Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. European Journal of Cancer. 69. S131–S132. 4 indexed citations
3.
Medley, Louise, Alain Morel, David Farrugia, et al.. (2011). Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. British Journal of Cancer. 104(7). 1067–1070. 25 indexed citations
4.
Khan, Omar, Andrew D. Blann, Miranda Payne, et al.. (2011). Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. British Journal of Cancer. 104(12). 1822–1827. 26 indexed citations
5.
Talbot, D C, Anna L Olsen, Valérie André, et al.. (2009). Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. Journal of Clinical Oncology. 27(15_suppl). 3507–3507. 6 indexed citations
6.
Steward, William P., Mark R. Middleton, Paul M. Loadman, et al.. (2007). The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study. Annals of Oncology. 18(6). 1098–1103. 34 indexed citations
7.
Schacter, Lee, D C Talbot, Peter Ellis, David J. Dunlop, & N. Thatcher. (2004). Safety and efficacy of DHA-paclitaxel (TXP) in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7111–7111. 3 indexed citations
8.
Braybrooke, Jeremy, C. Manegold, K. Mattson, et al.. (2003). Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. 41(2). 215–219. 15 indexed citations
9.
Levitt, N C, Ferry A.L.M. Eskens, Kenneth J. O’Byrne, et al.. (2001). Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.. PubMed. 7(7). 1912–22. 106 indexed citations
10.
Propper, David, Jeremy Braybrooke, N C Levitt, et al.. (2000). Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer. 82(11). 1759–1763. 14 indexed citations
11.
Hope, Tony, et al.. (1999). The development of a structured rating schedule (the BAS) to assess skills in breaking bad news. British Journal of Cancer. 80(5-6). 792–800. 38 indexed citations
12.
Saunders, Mark, A. J. Salisbury, Kenneth J. O’Byrne, et al.. (1998). A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine.. PubMed. 17(6D). 4677–80. 2 indexed citations
13.
Giatromanolaki, Alexandra, Kenneth J. O’Byrne, Stephen Fox, et al.. (1996). PROGNOSTIC VALUE OF ANGIOGENESIS IN OPERABLE NON-SMALL CELL LUNG CANCER. The Journal of Pathology. 179(1). 80–88. 148 indexed citations
14.
Talbot, D C, Justin H. Davies, KA MacLennan, & I. E. Smith. (1994). Signet-ring cell lymphoma of bone marrow.. Journal of Clinical Pathology. 47(2). 184–186. 8 indexed citations
15.
Fife, Kate, et al.. (1992). Chylous ascites in Kaposi's sarcoma: a case report. British Journal of Dermatology. 126(4). 378–379. 9 indexed citations
16.
Talbot, D C & I E Smith. (1992). New perspectives in lung cancer.5. New drugs in lung cancer.. Thorax. 47(3). 188–194. 4 indexed citations
17.
Talbot, D C, Ian E. Smith, Janine Mansi, et al.. (1991). Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.. Journal of Clinical Oncology. 9(12). 2141–2147. 55 indexed citations
18.
Smith, C., S. Milliken, R Powles, et al.. (1990). Teicoplanin compared to flucloxacillin for antibiotic treatment of neutropenic patients. British Journal of Haematology. 76(s2). 6–9. 5 indexed citations
19.
Talbot, D C, et al.. (1988). A Randomized Double-Blind Placebo Controlled Trial of Medroxyprogesterone Acetate (Mpa) in Cancer Cachexia. British Journal of Cancer. 58. 267–267. 5 indexed citations
20.
Talbot, D C, et al.. (1977). Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2. JNCI Journal of the National Cancer Institute. 58(1). 91–97. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Els O. Witteveen Breakdown of academic impact, for papers by Pentti J. Taskinen Breakdown of academic impact, for papers by Ines Abbate Breakdown of academic impact, for papers by Darlene Gibbon Breakdown of academic impact, for papers by Patrizia Serra Breakdown of academic impact, for papers by Adam Maciejczyk Breakdown of academic impact, for papers by Yiqun Zhang Breakdown of academic impact, for papers by Qing Zhou Breakdown of academic impact, for papers by P. Dodion Breakdown of academic impact, for papers by CA Eekman
Rankless by CCL
2026